title: Regulatory forum opinion piece*: tissue cross-reactivity studies: what constitutes an adequate positive control and how do we report positive staining?
authors.affiliation: Drug Safety Research & Development, Pfizer Worldwide Research & Development, Groton, Connecticut, USA frank.j.geoly@pfizer.com.
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Geoly
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D003429:Cross Reactions; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000592:standards*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods / Q000592:standards*; D008954:Models, Biological; D018570:Risk Assessment / Q000379:methods / Q000592:standards*
chemical_list: D000911:Antibodies, Monoclonal
keywords: commentary.; immunohistochemistry methods; interpretation; regulatory affairs; safety assessment; tissue cross-reactivity